Fish & Richardson - News and Alerts
1160
page,page-id-1160,page-template-default,logged-in,admin-bar,no-customize-support,ajax_fade,page_not_loaded,,select-child-theme-ver-1.0.0,select-theme-ver-3.5.2,menu-animation-underline,smooth_scroll,wpb-js-composer js-comp-ver-4.11.2.1,vc_responsive

News & Events

Alerts

August 2, 2017

PTAB Splits on Instituting Challenges to Herceptin® Patents

On July 27th, the PTAB issued institution decisions in five IPRs brought by Hospira challenging four Genentech patents related to Herceptin® (trastuzumab).  The patents are directed to various methods of treating cancer patients with combination therapies incorporating anti-ErbB2 antibodies.  Three challenges were instituted (IPR2017-00737, -00804, and -00805), and two were denied (IPR2017-00731 and -00739).  These decisions mark a new point in the challenge to Herceptin® patents, which have been challenged in IPRs more than any other biologic drug—seventeen times in 2017 alone.

July 12, 2017

Pfizer Takes Aim at Herceptin® Patent at the PTAB

Pfizer has shown its muscle in the biosimilars field, purchasing Hospira in 2015 and launching the second biosimilar on the U.S. market, Inflectra® (infliximab), a biosimilar of Johnson & Johnson’s Remicade®. Pfizer is now eying Genentech’s Herceptin (trastuzumab), which was first FDA approved for metastatic breast cancer in 1998. Pfizer filed two IPRs on June 30th challenging a Herceptin® patent, U.S. Patent No. 8,591,897.  The ’897 patent is directed to methods of treating patients with non-metastatic HER2-positive breast cancer by administering anthracycline/cyclophosphamide (AC) based chemotherapy, followed by sequential administration of a taxoid and trastuzumab. The earliest priority date on the face of the ’897 patent is May 2005.

June 20, 2017

Kyle Bass Ends with a Bang: Success in Final PTAB Decision

On June 7, 2017, Kyle Bass received his last final written decision in a long list of PTAB decisions rendered over the past two years as Kyle Bass sought to invalidate pharma patents.  U.S. Patent No. 8,476,010 (the “’010 patent”) is owned by Fresenius Kabi USA, and is the only Orange Book patent covering Fresenius’ anesthetic drug Diprivan®.  The Board found all challenged claims unpatentable as obvious.

June 14, 2017

Tasha Francis, Will Orlady and Dorothy Whelan Author NYIPLA Article, “Recent Developments in Biopharma PTAB Practice”

Tasha Francis, Ph.D., Will Orlady, and Dorothy Whelan authored “Recent Developments in Biopharma PTAB Practice,” in the February/March 2017 issue of The Report – NYIPLA.

June 13, 2017

PTAB Rules in Favor of Fish Client Coherus BioSciences in Two More IPR Decisions

On June 9, 2017, the Patent Trial and Appeal Board ruled in favor of Coherus’ petitions for inter partes review (IPR) of AbbVie’s U.S. Patent 9,073,987 (‘987 Patent) and U.S. Patent 9,017,680 (‘680 Patent). The PTAB’s decision invalidates all claims of the patents that were directed to a method of treating rheumatoid arthritis.  Back on May 16, Coherus prevailed at the PTAB in a similar IPR proceeding involving AbbVie’s U.S. Patent 8,889,135 (‘135 Patent).

Fill out the form below to receive our monthly newsletter and updates on your selected areas of interest. You can unsubscribe at any time by clicking the unsubscribe link at the bottom of the email.

  • This field is for validation purposes and should be left unchanged.